Activation of Protease-Activated Receptor-2 Leads to Inhibition of Osteoclast Differentiation
- 1 March 2004
- journal article
- Published by Oxford University Press (OUP) in Journal of Bone and Mineral Research
- Vol. 19 (3) , 507-516
Abstract
PAR-2 is expressed by osteoblasts and activated by proteases present during inflammation. PAR-2 activation inhibited osteoclast differentiation induced by hormones and cytokines in mouse bone marrow cultures and may protect bone from uncontrolled resorption. Introduction: Protease-activated receptor-2 (PAR-2), which is expressed by osteoblasts, is activated specifically by a small number of proteases, including mast cell tryptase and factor Xa. PAR-2 is also activated by a peptide (RAP) that corresponds to the “tethered ligand” created by cleavage of the receptor's extracellular domain. The effect of activating PAR-2 on osteoclast differentiation was investigated. Materials and Methods: Mouse bone marrow cultures have been used to investigate the effect of PAR-2 activation on osteoclast differentiation induced by parathyroid hormone (PTH), 1,25 dihydroxyvitamin D3 [1,25(OH)2D3], and interleukin-11 (IL-11). Expression of PAR-2 by mouse bone marrow, mouse bone marrow stromal cell-enriched cultures, and the RAW264.7 osteoclastogenic cell line was demonstrated by RT-PCR. Results: RAP was shown to inhibit osteoclast differentiation induced by PTH, 1,25(OH)2D3, or IL-11. Semiquantitative RT-PCR was used to investigate expression of mediators of osteoclast differentiation induced by PTH, 1,25(OH)2D3, or IL-11 in mouse bone marrow cultures and primary calvarial osteoblast cultures treated simultaneously with RAP. In bone marrow and osteoblast cultures treated with PTH, 1,25(OH)2D3, or IL-11, RAP inhibited expression of RANKL and significantly suppressed the ratio of RANKL:osteoprotegerin expression. Activation of PAR-2 led to reduced expression of prostaglandin G/H synthase-2 in bone marrow cultures treated with PTH, 1,25(OH)2D3, or IL-11. RAP inhibited PTH- or 1,25(OH)2D3-induced expression of IL-6 in bone marrow cultures. RAP had no effect on osteoclast differentiation in RANKL-treated RAW264.7 cells. Conclusion: These observations indicate that PAR-2 activation inhibits osteoclast differentiation by acting on cells of the osteoblast lineage to modulate multiple mediators of the effects of PTH, 1,25(OH)2D3, and IL-11. Therefore, the role of PAR-2 in bone may be to protect it from uncontrolled resorption by limiting levels of osteoclast differentiation.Keywords
This publication has 38 references indexed in Scilit:
- Protease‐Activated Receptors: A Means of Converting Extracellular Proteolysis into Intracellular SignalsIUBMB Life, 2002
- Increased Marrow-Derived Osteoprogenitor Cells and Endosteal Bone Formation in Mice Lacking Thrombospondin 2Journal of Bone and Mineral Research, 2000
- Expression of protease-activated receptor-2 by osteoblastsBone, 2000
- Modulation of Osteoblast-like Cell Behavior by Activation of Protease-Activated Receptor-1Journal of Bone and Mineral Research, 1999
- Immunolocalization of protease‐activated receptor‐2 in skin: receptor activation stimulates interleukin‐8 secretion by keratinocytes in vitroImmunology, 1998
- Expression of the Thrombin Receptor in Developing Bone and Associated TissuesJournal of Bone and Mineral Research, 1998
- Regulation of interleukin‐6 and interleukin‐6R α (gp80) expression by murine immunoglobulin‐secreting B‐cell hybridomasImmunology, 1998
- The Mouse Proteinase-activated Receptor-2 cDNA and GeneJournal of Biological Chemistry, 1995
- Murine osteoclasts and spleen cell polykaryons are distinguished by mRNA phenotypingJournal of Bone and Mineral Research, 1994
- Interleukin-11: a new cytokine critical for osteoclast development.Journal of Clinical Investigation, 1994